The effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced retinopathy.

(A) A schematic diagram depicting the time course of our experiment. (B) Whole-mounted stained retinas on day 2 after injection. (C) The reduction of the NVT area was observed in aflibercept injected eyes, but not in ranibizumab injected eyes. (D) Avascular area enlargement was observed in aflibercept injected eyes, but not in ranibizumab injected eyes. (E) Decreased sinuosity of the retinal vessel was observed in aflibercept injected eyes, but not in ranibizumab injected eyes. (F) Retinal vascular permeability was suppressed in aflibercept-treated eyes, but not in ranibizumab-treated eyes (arrowheads). Scale bars represent 1000 μm (B and upper row of F); 200 μm (lower row of F); **PP<0.05 (n = 7 /group). Data are presented as mean ± SD. PBS, phosphate-buffered saline solution; IVA, intravitreal aflibercept; IVR, intravitreal ranibizumab; NVT, neovascular tuft; NS, not significant.